Achilles Therapeutics Analyst Ratings
Achilles Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/07/2022 | 433.33% | Piper Sandler | $10 → $8 | Maintains | Overweight |
| 04/26/2021 | 633.33% | JP Morgan | → $11 | Initiates Coverage On | → Underweight |
| 04/26/2021 | 1233.33% | B of A Securities | → $20 | Initiates Coverage On | → Buy |
| 04/26/2021 | 1700% | Chardan Capital | → $27 | Initiates Coverage On | → Buy |
| 04/26/2021 | 1566.67% | Piper Sandler | → $25 | Initiates Coverage On | → Overweight |
| 04/26/2021 | 1433.33% | Oppenheimer | → $23 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 12/07/2022 | 433.33% | 派珀·桑德勒 | $10 → $8 | 維護 | 超重 |
| 04/26/2021 | 633.33% | 摩根大通 | → $11 | 開始承保 | →減持 |
| 04/26/2021 | 1233.33% | B of A證券 | → $20 | 開始承保 | →購買 |
| 04/26/2021 | 1700% | 查爾丹資本 | → $27 | 開始承保 | →購買 |
| 04/26/2021 | 1566.67% | 派珀·桑德勒 | → $25 | 開始承保 | →超重 |
| 04/26/2021 | 1433.33% | 奧本海默 | → $23 | 開始承保 | →跑贏大盤 |
What is the target price for Achilles Therapeutics (ACHL)?
阿喀琉斯療法(ACHL)的目標價格是多少？
The latest price target for Achilles Therapeutics (NASDAQ: ACHL) was reported by Piper Sandler on December 7, 2022. The analyst firm set a price target for $8.00 expecting ACHL to rise to within 12 months (a possible 433.33% upside). 1 analyst firms have reported ratings in the last year.
派珀·桑德勒於2022年12月7日報道了阿喀琉斯治療公司(納斯達克：ACHL)的最新目標價。這家分析公司將目標價定為8美元，預計ACHL將在12個月內上漲至(可能上漲433.33%)。1家分析公司在過去一年公佈了評級。
What is the most recent analyst rating for Achilles Therapeutics (ACHL)?
阿基裡斯治療公司(ACHL)的最新分析師評級是多少？
The latest analyst rating for Achilles Therapeutics (NASDAQ: ACHL) was provided by Piper Sandler, and Achilles Therapeutics maintained their overweight rating.
派珀·桑德勒對阿喀琉斯治療公司(納斯達克代碼：ACHL)的最新分析師評級是由派珀·桑德勒提供的，阿喀琉斯治療公司維持其增持評級。
When is the next analyst rating going to be posted or updated for Achilles Therapeutics (ACHL)?
阿喀琉斯治療公司(ACHL)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Achilles Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Achilles Therapeutics was filed on December 7, 2022 so you should expect the next rating to be made available sometime around December 7, 2023.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與阿喀琉斯治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。阿喀琉斯治療公司的上一次評級是在2022年12月7日提交的，所以你應該預計下一次評級將在2023年12月7日左右提供。
Is the Analyst Rating Achilles Therapeutics (ACHL) correct?
分析師對阿喀琉斯治療公司(ACHL)的評級正確嗎？
While ratings are subjective and will change, the latest Achilles Therapeutics (ACHL) rating was a maintained with a price target of $10.00 to $8.00. The current price Achilles Therapeutics (ACHL) is trading at is $1.50, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的跟腱治療(ACHL)評級保持不變，目標價在10.00美元至8.00美元之間。阿喀琉斯治療公司(ACHL)目前的交易價格為1.50美元，超出了分析師的預測範圍。